Deciphera Pharmaceuticals Net Income 2016-2021 | DCPH

Deciphera Pharmaceuticals net income from 2016 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Deciphera Pharmaceuticals Annual Net Income
(Millions of US $)
2020 $-266
2019 $-192
2018 $-100
2017 $-50
2016 $-26
2015 $-20
Deciphera Pharmaceuticals Quarterly Net Income
(Millions of US $)
2021-09-30 $-80
2021-06-30 $-70
2021-03-31 $-61
2020-12-31 $-63
2020-09-30 $-64
2020-06-30 $-67
2020-03-31 $-73
2019-12-31 $-67
2019-09-30 $-56
2019-06-30 $-21
2019-03-31 $-47
2018-12-31 $-32
2018-09-30 $-24
2018-06-30 $-22
2018-03-31 $-21
2017-12-31 $-20
2017-09-30 $-12
2017-06-30 $-11
2017-03-31 $-8
2016-12-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.519B $0.042B
Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69